针对心血管疾病预防的核酸向疗法的进展
Umidakhon Makhmudova1,2,3, Elisabeth Steinhagen-Thiessen2,3,4, Massimo Volpe5,6
1Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Berlin, Hindenburgdamm 30, 12203 Berlin, Germany.
Cardiovascular research
|July 6, 2024
概括
抗意义寡核酸 (ASO) 和小干扰RNA (siRNA) 等核酸疗法通过向参与脂质代谢和高血压的基因来预防心血管疾病 (CVD) 是有前途的.
科学领域:
- 心血管医学 心血管医学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 基于核酸的疗法正在迅速发展,用于预防心血管疾病 (CVD).
- 这些疗法提供了新的方法来调节传统药物无法处理的目标.
- 在过去的十年中,在输送,安全性和有效性方面取得了重大进展.
研究的目的:
- 审查RNA向疗法的转化为预防心血管疾病的临床研究.
- 要总结siRNA,ASO和基因编辑用于失脂症和高血压的应用.
- 概述心血管医学未来的创新治疗选择.
主要方法:
- 关于针对心血管疾病的核酸向治疗的当前文献的综述.
- 对siRNA,ASO和基因编辑的临床开发计划的分析.
- 专注于脂质代谢 (PCSK9,ApoA,ApoC3,ANGPTL3) 和高血压 (AGT) 的目标.
主要成果:
- 包括siRNA和ASO在内的RNA向疗法正在迅速进入临床试验.
- 这些疗法显示出治疗脱脂症和动脉高血压的潜力.
- 基因编辑和基因转移正在针对低密度脂蛋白受体缺乏症等疾病进行调查.
结论:
- 基于核酸的疗法在预防心血管疾病方面取得了重大进展.
- 向肝脏产生的异位性脂蛋白和血管增生素是关键策略.
- 这些创新方法对心血管医学的未来有着巨大的前景.
关键词:
在 AGT AGT AGT AGTANGPTL3 在线观看APOBOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB APOB在APOC3中使用APOC3.在ASO的基础上,ASO是ASO.动脉高血压是一种高血压.基础编辑器 基础编辑器这就是CRISPR/Cas9的作用.预防心血管疾病脱脂血症是什么意思 脱脂血症是什么意思这种LDL-R是LDL-R的.在LPA LPA LPA中使用.在PCSK9中这就是SiRNA SiRNA.相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
514
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
514
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
74
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
74
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Gene Therapy
25.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K


